
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">CRG</journal-id><journal-title-group><journal-title>Case Reports in Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1662-0631</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH-4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29805355</article-id><article-id pub-id-type="pmc">5968254</article-id><article-id pub-id-type="doi">10.1159/000479494</article-id><article-id pub-id-type="publisher-id">crg-0012-0125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Epinephrine in the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Preliminary Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hatami</surname><given-names>Behzad</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kashfi</surname><given-names>Seyed Mohammad Hossein</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abbasinazari</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nazemalhosseini Mojarad</surname><given-names>Ehsan</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pourhoseingholi</surname><given-names>Mohammad Amin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zali</surname><given-names>Mohammad Reza</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mohammad Alizadeh</surname><given-names>Amir Houshang</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><sup>b</sup>Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor1">*Prof. Amir Houshang Mohammad Alizadeh, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Taleghani Hospital, Parvaneh Ave., Tabnak Str., PO Box 19835-178, Evin, Tehran 19857 (Iran), E-Mail <email>ahmaliver@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Apr</season><year>2018</year></pub-date><pub-date pub-type="epub"><day>13</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>12</volume><issue>1</issue><fpage>125</fpage><lpage>136</lpage><history><date date-type="received"><day>9</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 by S. Karger AG, Basel</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.</license-p></license></permissions><abstract><sec><title>Background</title><p>Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The incidence of post-ERCP pancreatitis (PEP) ranges between 15 and 20% among patients at high risk of developing PEP. The efficacy of indomethacin administration in the prevention of PEP is rather debatable. In the present randomized trial study, we evaluated whether or not the combination of indomethacin and epinephrine in comparison to the single administration of indomethacin differs in the pathogenesis and prevention of post-ERCP pancreatitis.</p></sec><sec><title>Patients and Methods</title><p>One hundred and ninety-two patients were randomized in a double-blinded manner into 3 groups: the epinephrine group (group A), the indomethacin group (group B), and the combined epinephrine and indomethacin group (group C). After the procedure, patients were evaluated for the PEP development.</p></sec><sec><title>Results</title><p>During the procedure, 66 patients were randomized to the epinephrine group (group A), 68 cases to the indomethacin group (group B), and 58 individuals to the indomethacin-epinephrine group (group C). The mean age of patients in the epinephrine group was 59.59 &#x000b1; 15.680 years, in the indomethacin group it was 58.06 &#x000b1; 17.125 years, and in the combination group it was 59.62 &#x000b1; 15.369 years. In the present study, we did not observe a significant difference between the 3 groups in sex, age, pre-ERCP amylase, lipase, and patient and procedure risk factors including pancreatic duct (PD) dilation (<italic>p</italic> = 0.404), PD cannulation (<italic>p</italic> = 0.329), and difficult cannulation (<italic>p</italic> = 0.076) among others. PEP developed in 7 of the 192 individuals (3.6%), 6 PEP cases occurred in the indomethacin group and 1 in the epinephrine group (<italic>p</italic> = 0.016). Univariate analysis of risk factors for PEP in patients with and without pancreatitis revealed no significant difference between the pancreatitis group and the non-pancreatitis group.</p></sec><sec><title>Conclusion</title><p>In comparison to the administration of indomethacin alone, a single application of epinephrine and the combination of epinephrine and indomethacin seem to be effective in reducing the cases of PEP. A further randomized clinical trial with a larger sample size is required to confirm the efficacy of our medication in the prevention of pancreatitis after ERCP.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Endoscopic retrograde cholangiopancreatography</kwd><kwd>Post-endoscopic retrograde cholangiopancreatography pancreatitis</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="42"/><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1_1"><title>Introduction</title><p>Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP) [<xref rid="B1" ref-type="bibr">1</xref>]. The incidence of post-ERCP pancreatitis (PEP) ranges between 15 and 20% among patients at high risk of developing PEP [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. The pathogenesis of acute pancreatitis is not clearly identified. It has been reported that an aberrant calcium signaling pathway and reactive oxygen species might lead to autodigestion of the pancreas by its own proteases [<xref rid="B4" ref-type="bibr">4</xref>]. Therefore, several studies were carried out to identify the mechanisms underlying PEP in high-risk patients. However, papillary edema has been the focal point [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Many different approaches have been applied in order to reduce the risk of PEP in patients and several pharmacologic agents have been examined for their effect on reducing the incidence rate and severity of PEP. Among these prophylactic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), especially indomethacin and diclofenac, have previously been evaluated in several randomized controlled trials [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. Via inhibiting phospholipase A2 (PLA2), NSAIDs play a significant role in the prevention of acute pancreatitis [<xref rid="B9" ref-type="bibr">9</xref>]. Other pharmacologic agents have also been evaluated for their prophylactic effects on PEP including protease inhibitors such as gabexate, ulinastatin, and nafamostat mesylate [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>] and vasoactive mediators including lidocaine, nifedipine, epinephrine, and glyceryltrinitrate [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. The efficacy of indomethacin in the prevention of pancreatitis after ERCP is rather debatable with some studies supporting its significant role in reducing the severity and incidence of pancreatitis [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>], while others indicated the lack of any improvement in the case of indomethacin administration [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. On the other hand, topical pharmacologic agents have had some benefits over other interventions. In this regard, the role of local administration of epinephrine on reducing the incidence and severity of PEP has been reported in several studies [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. The objective of this prospective randomized trial study was to evaluate whether or not the combination of indomethacin and epinephrine in comparison to the single administration of indomethacin differs in the pathogenesis and prevention of PEP.</p></sec><sec sec-type="subjects|methods" id="sec1_2"><title>Patients and Methods</title><p>This study was designed as a randomized, prospective, double-blind trial. Informed consent was obtained from all individuals and the research proposal was approved by the ethics committee of the Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. From April 2013 to October 2014, patients who referred to the Endoscopy Unit of Taleghani Hospital for ERCP were recruited into this prospective study. A total of 293 patients underwent therapeutic ERCP; however, 101 patients were excluded from the study according to our exclusion criteria. Ultimately, 192 patients (98 male and 94 female) were included in this study. The age of the individuals ranged between 18 and 89 years. The mean age of patients was 59.06 &#x000b1; 16.049 years. The demographic characteristics of the patients in this study are shown in Table <xref ref-type="table" rid="T1">1</xref>. Exclusion criteria were as follows: the pancreatic duct (PD) stent placement, history of acute pancreatitis, age under 18 years, prior endoscopic sphincterotomy, chronic pancreatitis with an acute exacerbation, an elevated serum amylase or lipase level (more than the upper normal limit: &#x0003e; 100 and &#x0003e; 60 IU/L, respectively), and an allergy to epinephrine. Patients who fulfilled the inclusion criteria were randomized into study groups. High-risk patients were defined as follows: suspected sphincter of Oddi dysfunction (SOD), precut biliary sphincterotomy, PD cannulation (at least once), endoscopic balloon dilation (after sphincterotomy), and the presence of more than two of the other risk factors including female sex, age &#x0003c; 40 years, nondilated common bile duct (CBD), normal bilirubin, and difficult cannulation [<xref rid="B24" ref-type="bibr">24</xref>].</p><sec id="sec2_1"><title>Study Design</title><p>The patients were randomized in a double-blinded manner into 3 groups: the epinephrine group (group A), the indomethacin group (group B), and the combined epinephrine and indomethacin group (group C). Randomization and administration of epinephrine or indomethacin were done by personnel who were not involved in the endoscopic procedure. The allocation was done using the random number generated by a computer. Each patient had a number corresponding to these random numbers and they were included in their specific group by this pattern. During the procedure, patients randomly received a spray of 10 ml epinephrine (diluted to 1/10,000 in saline) on the major papilla (immediately after ERCP) and a suppository placebo tablet (group A) or a suppository containing 100 mg of indomethacin (immediately after procedure) and normal saline solution sprayed on the major papilla (group B), or a combination of epinephrine on the major papilla and administration of 100 mg of indomethacin (group C). After the procedure, patients were evaluated for the PEP development.</p></sec><sec id="sec2_2"><title>Definition of PEP</title><p>Serum amylase and lipase concentrations were measured and recorded before ERCP, 4 and 24 h after ERCP as indicated in Table <xref ref-type="table" rid="T1">1</xref>. PEP was defined as an elevation of serum amylase levels more than threefold of the upper normal limit associated with at least two clinical symptoms including abdominal pain or tenderness, backache, nausea, and vomiting. The normal upper limit of serum amylase is 100 IU/L. The severity of PEP was classified as mild, moderate, or severe according to consensus classification [<xref rid="B25" ref-type="bibr">25</xref>]. We included patients with suspected SOD and we did not use manometry for the definition of SOD. Patients were prospectively evaluated for the occurrence of PEP between the groups.</p></sec><sec id="sec2_3"><title>Statistical Analysis</title><p>All quantitative variables were indicated as mean &#x000b1; SD. The 3 groups were evaluated for statistical analysis. For the continuous variables, the analysis of variance was performed and the comparison between the groups was also assessed by the &#x003c7;<sup>2</sup> test or the Fisher exact test. A <italic>p</italic> value of less than 0.05 was considered a statistical significance between the groups. According to Sotoudehmanesh et al. [<xref rid="B7" ref-type="bibr">7</xref>], in the case of any significant effect, relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) were computed with their 95% CI.</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>During 2013&#x02013;2014, 293 patients underwent therapeutic ERCP; however, 101 patients were excluded from the study according to our exclusion criteria: prior endoscopic sphincterotomy (<italic>n</italic> = 6&#x02013;8), PD stent placement (<italic>n</italic> = 9), history of acute pancreatitis (<italic>n</italic> = 7), age under 18 years (<italic>n</italic> = 6), chronic pancreatitis with an acute exacerbation (<italic>n</italic> = 5), an elevated serum amylase or lipase level (more than the upper normal limit: &#x0003e; 100 and &#x0003e; 60 IU/L, respectively) (<italic>n</italic> = 4), and an allergy to epinephrine (<italic>n</italic> = 2). Ultimately, 192 patients were recruited. During the ERCP, among 192 patients, 66 were randomized to the epinephrine group (group A), 68 to the indomethacin group (group B), and 58 to the combined indomethacin-epinephrine group (group C) (Fig. <xref ref-type="fig" rid="F1">1</xref>). The mean age of patients in the epinephrine group was 59.59 &#x000b1; 15.680 years, in the indomethacin group it was 58.06 &#x000b1; 17.125 years, and in the combination group it was 59.62 &#x000b1; 15.369 years.</p><sec id="sec2_4"><title>Procedure Outcomes</title><p>In the present study, we did not observe a significant difference between the 3 groups in sex, age, pre-ERCP amylase, lipase, PD dilation (<italic>p</italic> = 0.404), PD cannulation (<italic>p</italic> = 0.329), difficult cannulation (<italic>p</italic> = 0.076), sphincterotomy (<italic>p</italic> = 0.421), needle knife precut (<italic>p</italic> = 0.610), PD injection (<italic>p</italic> = 0.687), balloon dilation of sphincter of Oddi (<italic>p</italic> = 0.533), biliary stricture (<italic>p</italic> = 0.712), biliary duct tumor (<italic>p</italic> = 0.389), peri-ampullary diverticulum (<italic>p</italic> = 0.872), and suspected SOD (<italic>p</italic> = 0.808). In this study, PEP developed in 7 of the 192 individuals (3.6%), 6 PEP occurred in the indomethacin group and 1 case in the epinephrine group. However, none of the patients in the combination group (epinephrine and indomethacin) developed pancreatitis (<italic>p</italic> = 0.016) (Table <xref ref-type="table" rid="T2">2</xref>). Univariate analysis of risk factors for PEP in patients with and without pancreatitis is presented in Table <xref ref-type="table" rid="T3">3</xref>. In this study, there was no death due to pancreatitis in the related patients. There was no significant difference between the pancreatitis group and the non-pancreatitis group according to PD dilation (0.739), suspected SOD (0.739), cholecystectomy (0.581), CBD stone (0.355), difficult cannulation (0.343), sphincterotomy (0.134), needle knife precut (0.403), PD cannulation (0.368), PD injection (0.798), balloon dilation of the sphincter of Oddi (0.419), CBD dilation (0.571), biliary stricture (0.330), biliary duct tumor (0.462), and peri-ampullary diverticulum (0.571) (Table <xref ref-type="table" rid="T3">3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>Several pharmacologic components and endoscopic interventions have been utilized in order to prevent PEP. These are including anti-secretory agents, sphincter relaxants, anti-inflammatory agents, antioxidants, and protease inhibitors among others. Among these agents, however, indomethacin as a safe, inexpensive, available, easy-to-administer agent, which is associated with few side effects, has been shown to be effective in reducing the severity of PEP in previous studies [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>], whereas a number of other studies indicated a null effect of indomethacin in preventing PEP [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. On the other hand, topical application of epinephrine as a vasoactive mediator has been reported to reduce PEP via decreasing the papillary edema. Lately, combination therapy has been emerged as an efficacious approach in preventing PEP [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. In this prospective randomized trial study, we evaluated whether or not the combination of indomethacin and epinephrine differs in the pathogenesis and prevention of PEP. In our study, we found that among 68 patients in the indomethacin group, 6 individuals developed pancreatitis; however, in the epinephrine group only 1 patient developed pancreatitis (1/66). Among the 58 patients who received the combination medication, none developed pancreatitis. To our knowledge, this is the first report of epinephrine and indomethacin combination efficacy in preventing PEP. According to our findings, we observed that the single application of epinephrine and the combination of epinephrine and indomethacin significantly reduced the risk of PEP (<italic>p</italic> = 0.016). The ERCP procedure might result in local or systemic inflammatory response, which is the precursor of PEP [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. Furthermore, PLA2 has a vital role in the development of this inflammatory response [<xref rid="B33" ref-type="bibr">33</xref>]. It has been demonstrated that the mechanisms of NSAIDs in the prevention of PEP is to suppress peculiar molecular pathways that contributed to prostaglandin synthesis, PLA2, and neutrophil-endothelial cell attachment [<xref rid="B33" ref-type="bibr">33</xref>]. Indomethacin as an important inhibitor of PLA2 and its role in the prevention of PEP has been evaluated in several previous studies [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. In line with our study, Elmunzer et al. [<xref rid="B35" ref-type="bibr">35</xref>] evaluated the efficacy of rectal indomethacin on 602 patients who underwent ERCP. They observed that rectal indomethacin significantly decreased the PEP incidence and severity. Among 79 patients who developed pancreatitis, 27 (9.2%) were in the indomethacin group. However, in our study, the majority of patients who developed pancreatitis (6/7) were in the indomethacin group, and in comparison to the application of indomethacin and epinephrine combination, patients were at high risk of developing PEP (<italic>p</italic> = 0.016). In contrast to our study, a meta-analysis by Yaghoobi et al. [<xref rid="B19" ref-type="bibr">19</xref>] showed that rectal administration of indomethacin significantly decreased the PEP risk to half in related patients. In another study on the Iranian population, Sotoudehmanesh et al. [<xref rid="B7" ref-type="bibr">7</xref>] reported that administration of rectal indomethacin reduced the risk of PEP (<italic>p</italic> = 0.01, RRR = 88%, ARR = 0.16, NNT = 6). However, the recent study by D&#x000f6;br&#x000f6;nte et al. [<xref rid="B20" ref-type="bibr">20</xref>] revealed no benefit in the rectal application of indomethacin in reducing the incidence of PEP. This is consistent with their previous findings on 228 patients who underwent ERCP [<xref rid="B21" ref-type="bibr">21</xref>]. In our study, we excluded patients who underwent the placement of a stent in order to get a precise effect of the medication after the ERCP. There have been numerous studies that evaluated the efficacy of pancreatic duct stent placement and the prevention of PEP [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>]. However, pharmacological agents have several benefits over stents including the cost benefit, ease of administration, minimal side effects, and widespread availability. Thus, despite the high efficacy of pancreatic stenting placement, it is not performed widely and one fifth of specialists prefer not to place pancreatic stents in any condition [<xref rid="B39" ref-type="bibr">39</xref>]. On the other hand, in an ad hoc analysis, Elmunzer et al. [<xref rid="B40" ref-type="bibr">40</xref>] showed that rectal indomethacin could replace PD stent placement in high-risk cases and a meta-analysis by Puig et al. [<xref rid="B27" ref-type="bibr">27</xref>] revealed that NSAIDs were effective either in the absence or presence of a pancreatic stent. The topical application of epinephrine and its role in the prevention of PEP has also been evaluated in several previous studies [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>]. Matsushita et al. [<xref rid="B5" ref-type="bibr">5</xref>] observed that among 370 patients undergoing diagnostic ERCP, PEP developed in 4 cases (1.1%) in the control group, whereas no PEP occurred in the epinephrine group (0/185) (<italic>p</italic> = 0.1230); they found that epinephrine sprayed on the papilla tended to reduce PEP; however, it was not statistically significant. One of the vital roles of epinephrine is the ability to decline edema and pancreatic ductal outflow obstruction, which is associated with the pathogenesis and progression of PEP [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. In another valuable study, Xu et al. [<xref rid="B42" ref-type="bibr">42</xref>] evaluated the efficacy of epinephrine in a series of 461 patients and observed that PEP occurred in 9/461 individuals (6.45%); however, the incidence rate was higher in the control group (31/480, 1.95%). Therefore, applying epinephrine was a promising approach and reduced the incidence of pancreatitis after ERCP (<italic>p</italic> = 0.0086). A valuable meta-analysis by Akshintala et al. [<xref rid="B41" ref-type="bibr">41</xref>] evaluated the efficacy of several pharmacological agents for the prevention of PEP including NSAIDs, topical epinephrine, antibiotics, and nafamostat. They observed that in comparison to other agents, topical epinephrine had the most effect on reducing PEP with 85.9% followed by rectal NSAIDs with 58.1%. In the present study, there were some limitations: first, the patients included in this study were recruited from a single center; however, a multi-institutional registry is required to confirm our findings on combination efficacy of epinephrine and indomethacin. Second, due to our small sample size, we could not evaluate the effect of the putative medications on the severity of PEP in our patients.</p></sec><sec sec-type="conclusions" id="sec1_5"><title>Conclusion</title><p>In comparison to the administration of indomethacin alone, the combination of epinephrine and indomethacin seems to be effective in reducing PEP. A further randomized clinical trial with a larger sample size is required to confirm the efficacy of our medication in the prevention of pancreatitis after ERCP.</p></sec><sec id="sec1_6"><title>Statement of Ethics</title><p>Informed consent was obtained from all individuals and the research proposal was approved by the ethics committee of the Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</p></sec><sec id="sec1_7"><title>Disclosure Statement</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was accomplished by grant No. 744 from Shahid Beheshti University of Medical Sciences, Tehran, Iran. We thank all patients and their families who participated in this study.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andriulli</surname><given-names>A</given-names></name><name><surname>Loperfido</surname><given-names>S</given-names></name><name><surname>Napolitano</surname><given-names>G</given-names></name><name><surname>Niro</surname><given-names>G</given-names></name><name><surname>Valvano</surname><given-names>MR</given-names></name><name><surname>Spirito</surname><given-names>F</given-names></name><etal/></person-group><article-title>Incidence rates of post-ERCP complications: a systematic survey of prospective studies.</article-title><source>Am J Gastroenterol.</source><year>2007</year><month>8</month><volume>102</volume><issue>(8)</issue><fpage>1781</fpage><lpage>1788</lpage><pub-id pub-id-type="pmid">17509029</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>ZS</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>NH</given-names></name><name><surname>Fan</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Risk factors for ERCP-related complications: a prospective multicenter study.</article-title><source>Am J Gastroenterol.</source><year>2009</year><month>1</month><volume>104</volume><issue>(1)</issue><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19098846</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases.</article-title><source>Pancreatology.</source><year>2011</year><volume>11</volume><issue>(4)</issue><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">21894057</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerch</surname><given-names>MM</given-names></name><name><surname>Gorelick</surname><given-names>FS</given-names></name></person-group><article-title>Models of acute and chronic pancreatitis.</article-title><source>Gastroenterology.</source><year>2013</year><month>6</month><volume>144</volume><issue>(6)</issue><fpage>1180</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">23622127</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Takakuwa</surname><given-names>H</given-names></name><name><surname>Shimeno</surname><given-names>N</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nishio</surname><given-names>A</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name></person-group><article-title>Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis.</article-title><source>J Gastroenterol.</source><year>2009</year><volume>44</volume><issue>(1)</issue><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">19159075</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarnasky</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>J</given-names></name><name><surname>Cotton</surname><given-names>P</given-names></name><name><surname>Hoffman</surname><given-names>B</given-names></name><name><surname>Palesch</surname><given-names>Y</given-names></name><name><surname>Freeman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis.</article-title><source>Endoscopy.</source><year>1997</year><month>5</month><volume>29</volume><issue>(4)</issue><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">9255527</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotoudehmanesh</surname><given-names>R</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name><name><surname>Kolahdoozan</surname><given-names>S</given-names></name><name><surname>Ainechi</surname><given-names>S</given-names></name><name><surname>Malboosbaf</surname><given-names>R</given-names></name><name><surname>Nouraie</surname><given-names>M</given-names></name></person-group><article-title>Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.</article-title><source>Am J Gastroenterol.</source><year>2007</year><month>5</month><volume>102</volume><issue>(5)</issue><fpage>978</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">17355281</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoshbaten</surname><given-names>M</given-names></name><name><surname>Khorram</surname><given-names>H</given-names></name><name><surname>Madad</surname><given-names>L</given-names></name><name><surname>Ehsani Ardakani</surname><given-names>MJ</given-names></name><name><surname>Farzin</surname><given-names>H</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name></person-group><article-title>Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.</article-title><source>J Gastroenterol Hepatol.</source><year>2008</year><month>7</month><volume>23</volume><issue>(7 Pt 2)</issue><fpage>e11</fpage><lpage>e16</lpage><pub-id pub-id-type="pmid">17683501</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balmadrid</surname><given-names>B</given-names></name><name><surname>Kozarek</surname><given-names>R</given-names></name></person-group><article-title>Prevention and management of adverse events of endoscopic retrograde cholangiopancreatography.</article-title><source>Gastrointest Endosc Clin N Am.</source><year>2013</year><month>4</month><volume>23</volume><issue>(2)</issue><fpage>385</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">23540966</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>KS</given-names></name><name><surname>Huh</surname><given-names>KR</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>KO</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Hahn</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.</article-title><source>Pancreas.</source><year>2011</year><month>3</month><volume>40</volume><issue>(2)</issue><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">21206331</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manes</surname><given-names>G</given-names></name><name><surname>Ardizzone</surname><given-names>S</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Uomo</surname><given-names>G</given-names></name><name><surname>Pieramico</surname><given-names>O</given-names></name><name><surname>Porro</surname><given-names>GB</given-names></name></person-group><article-title>Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.</article-title><source>Gastrointest Endosc.</source><year>2007</year><month>6</month><volume>65</volume><issue>(7)</issue><fpage>982</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">17531632</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>YW</given-names></name><name><surname>Cha</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Na</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><etal/></person-group><article-title>The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.</article-title><source>Gut Liver.</source><year>2012</year><month>4</month><volume>6</volume><issue>(2)</issue><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">22570757</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prat</surname><given-names>F</given-names></name><name><surname>Amaris</surname><given-names>J</given-names></name><name><surname>Ducot</surname><given-names>B</given-names></name><name><surname>Bocquentin</surname><given-names>M</given-names></name><name><surname>Fritsch</surname><given-names>J</given-names></name><name><surname>Choury</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.</article-title><source>Gastrointest Endosc.</source><year>2002</year><month>8</month><volume>56</volume><issue>(2)</issue><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">12145597</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>JJ</given-names></name><name><surname>Lew</surname><given-names>RJ</given-names></name><name><surname>Ahmad</surname><given-names>NA</given-names></name><name><surname>Shah</surname><given-names>JN</given-names></name><name><surname>Ginsberg</surname><given-names>GG</given-names></name><name><surname>Kochman</surname><given-names>ML</given-names></name><etal/></person-group><article-title>The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis.</article-title><source>Gastrointest Endosc.</source><year>2004</year><month>2</month><volume>59</volume><issue>(2)</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">14745389</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>LH</given-names></name><name><surname>Qian</surname><given-names>JB</given-names></name><name><surname>Gu</surname><given-names>LG</given-names></name><name><surname>Qiu</surname><given-names>JW</given-names></name><name><surname>Ge</surname><given-names>ZM</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla.</article-title><source>J Gastroenterol Hepatol.</source><year>2011</year><month>7</month><volume>26</volume><issue>(7)</issue><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">21392105</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Chen</surname><given-names>MY</given-names></name><name><surname>Cai</surname><given-names>JT</given-names></name></person-group><article-title>Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis.</article-title><source>Dig Dis Sci.</source><year>2010</year><month>1</month><volume>55</volume><issue>(1)</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19160042</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelle</surname><given-names>EF</given-names></name><name><surname>Adham</surname><given-names>N</given-names></name><name><surname>Elashoff</surname><given-names>J</given-names></name><name><surname>Lewin</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>IL</given-names></name></person-group><article-title>Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice.</article-title><source>Gastroenterology.</source><year>1983</year><month>12</month><volume>85</volume><issue>(6)</issue><fpage>1307</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">6628928</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Altaf</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name></person-group><article-title>Rectal indomethacin for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials.</article-title><source>Turk J Gastroenterol.</source><year>2015</year><month>5</month><volume>26</volume><issue>(3)</issue><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">26006198</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaghoobi</surname><given-names>M</given-names></name><name><surname>Rolland</surname><given-names>S</given-names></name><name><surname>Waschke</surname><given-names>KA</given-names></name><name><surname>McNabb-Baltar</surname><given-names>J</given-names></name><name><surname>Martel</surname><given-names>M</given-names></name><name><surname>Bijarchi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Meta-analysis: rectal indomethacin for the prevention of post-ERCP pancreatitis.</article-title><source>Aliment Pharmacol Ther.</source><year>2013</year><month>11</month><volume>38</volume><issue>(9)</issue><fpage>995</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">24099466</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;br&#x000f6;nte</surname><given-names>Z</given-names></name><name><surname>Szepes</surname><given-names>Z</given-names></name><name><surname>Izb&#x000e9;ki</surname><given-names>F</given-names></name><name><surname>Gervain</surname><given-names>J</given-names></name><name><surname>Lakatos</surname><given-names>L</given-names></name><name><surname>P&#x000e9;csi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?</article-title><source>World J Gastroenterol.</source><year>2014</year><month>8</month><volume>20</volume><issue>(29)</issue><fpage>10151</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25110443</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;br&#x000f6;nte</surname><given-names>Z</given-names></name><name><surname>Toldy</surname><given-names>E</given-names></name><name><surname>M&#x000e1;rk</surname><given-names>L</given-names></name><name><surname>Sarang</surname><given-names>K</given-names></name><name><surname>Lakner</surname><given-names>L</given-names></name></person-group><article-title>Effects of rectal indomethacin in the prevention of post-ERCP acute pancreatitis.</article-title><source>Orv Hetil.</source><year>2012</year><month>6</month><volume>153</volume><issue>(25)</issue><fpage>990</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">22714033</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ooijen</surname><given-names>B</given-names></name><name><surname>Ouwendijk</surname><given-names>RJ</given-names></name><name><surname>Kort</surname><given-names>WJ</given-names></name><name><surname>Zijlstra</surname><given-names>FJ</given-names></name><name><surname>Vincent</surname><given-names>JE</given-names></name><name><surname>Wilson</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Raised plasma thromboxane B2 levels in experimental acute necrotizing pancreatitis in rats. The effects of flunarizine and indomethacin.</article-title><source>Scand J Gastroenterol.</source><year>1988</year><month>3</month><volume>23</volume><issue>(2)</issue><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">3363291</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akshintala</surname><given-names>VS</given-names></name><name><surname>Hutfless</surname><given-names>SM</given-names></name><name><surname>Colantuoni</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>KJ</given-names></name><name><surname>Khashab</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis.</article-title><source>Aliment Pharmacol Ther.</source><year>2013</year><month>12</month><volume>38</volume><issue>(11&#x02013;12)</issue><fpage>1325</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">24138390</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumonceau</surname><given-names>JM</given-names></name><name><surname>Andriulli</surname><given-names>A</given-names></name><name><surname>Deviere</surname><given-names>J</given-names></name><name><surname>Mariani</surname><given-names>A</given-names></name><name><surname>Rigaux</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>TH</given-names></name><etal/></person-group><article-title>European Society of Gastrointestinal Endoscopy. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis.</article-title><source>Endoscopy.</source><year>2010</year><month>6</month><volume>42</volume><issue>6</issue><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">20506068</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>PB</given-names></name><name><surname>Lehman</surname><given-names>G</given-names></name><name><surname>Vennes</surname><given-names>J</given-names></name><name><surname>Geenen</surname><given-names>JE</given-names></name><name><surname>Russell</surname><given-names>RC</given-names></name><name><surname>Meyers</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Endoscopic sphincterotomy complications and their management: an attempt at consensus.</article-title><source>Gastrointest Endosc.</source><year>1991</year><season>May-Jun</season><volume>37</volume><issue>(3)</issue><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">2070995</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildenhain</surname><given-names>PM</given-names></name><name><surname>Melhem</surname><given-names>MF</given-names></name><name><surname>Birsic</surname><given-names>WI</given-names></name><name><surname>Sell</surname><given-names>HW</given-names></name><name><surname>Rao</surname><given-names>KN</given-names></name></person-group><article-title>Acute hemorrhagic pancreatitis in mice: improved survival after indomethacin administration.</article-title><source>Digestion.</source><year>1989</year><volume>44</volume><issue>(1)</issue><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">2599282</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>I</given-names></name><name><surname>Calvet</surname><given-names>X</given-names></name><name><surname>Baylina</surname><given-names>M</given-names></name><name><surname>Isava</surname><given-names>&#x000c1;</given-names></name><name><surname>Sort</surname><given-names>P</given-names></name><name><surname>Lla&#x000f3;</surname><given-names>J</given-names></name><etal/></person-group><article-title>How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis.</article-title><source>PLoS One.</source><year>2014</year><month>3</month><volume>9</volume><issue>(3)</issue><comment>e92922.</comment></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>A</given-names></name><name><surname>Lum</surname><given-names>JT</given-names></name><name><surname>Lancaster</surname><given-names>C</given-names></name><name><surname>Olafsson</surname><given-names>AS</given-names></name><name><surname>Kolbasa</surname><given-names>KP</given-names></name><name><surname>Nezamis</surname><given-names>JE</given-names></name></person-group><article-title>Prevention by prostaglandins of caerulein-induced pancreatitis in rats.</article-title><source>Lab Invest.</source><year>1989</year><month>5</month><volume>60</volume><issue>(5)</issue><fpage>677</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">2469859</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsinelos</surname><given-names>P</given-names></name><name><surname>Fasoulas</surname><given-names>K</given-names></name><name><surname>Paroutoglou</surname><given-names>G</given-names></name><name><surname>Chatzimavroudis</surname><given-names>G</given-names></name><name><surname>Beltsis</surname><given-names>A</given-names></name><name><surname>Terzoudis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.</article-title><source>Endoscopy.</source><year>2012</year><month>1</month><volume>44</volume><issue>(1)</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">22198776</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotoudehmanesh</surname><given-names>R</given-names></name><name><surname>Eloubeidi</surname><given-names>MA</given-names></name><name><surname>Asgari</surname><given-names>AA</given-names></name><name><surname>Farsinejad</surname><given-names>M</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name></person-group><article-title>A randomized trial of rectal indomethacin and sublingual nitrates to prevent post-ERCP pancreatitis.</article-title><source>Am J Gastroenterol.</source><year>2014</year><month>6</month><volume>109</volume><issue>(6)</issue><fpage>903</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">24513806</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmunzer</surname><given-names>BJ</given-names></name><name><surname>Higgins</surname><given-names>PD</given-names></name><name><surname>Saini</surname><given-names>SD</given-names></name><name><surname>Scheiman</surname><given-names>JM</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Chak</surname><given-names>A</given-names></name><etal/></person-group><article-title>United States Cooperative for Outcomes Research in Endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data.</article-title><source>Am J Gastroenterol.</source><year>2013</year><month>3</month><volume>108</volume><issue>3</issue><fpage>410</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">23295278</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karne</surname><given-names>S</given-names></name><name><surname>Gorelick</surname><given-names>FS</given-names></name></person-group><article-title>Etiopathogenesis of acute pancreatitis.</article-title><source>Surg Clin North Am.</source><year>1999</year><month>8</month><volume>79</volume><issue>(4)</issue><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">10470320</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>V</given-names></name><name><surname>Leser</surname><given-names>HG</given-names></name><name><surname>Heinisch</surname><given-names>A</given-names></name><name><surname>Sch&#x000f6;lmerich</surname><given-names>J</given-names></name></person-group><article-title>Inflammatory mediators and cytokines &#x02013; new aspects of the pathophysiology and assessment of severity of acute pancreatitis?</article-title><source>Hepatogastroenterology.</source><year>1993</year><month>12</month><volume>40</volume><issue>(6)</issue><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">7509768</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>M</given-names></name><name><surname>Shokuhi</surname><given-names>S</given-names></name><name><surname>Christmas</surname><given-names>S</given-names></name><name><surname>Neoptolemos</surname><given-names>JP</given-names></name><name><surname>Slavin</surname><given-names>J</given-names></name></person-group><article-title>Inflammatory mediators in acute pancreatitis.</article-title><source>J Pathol.</source><year>2000</year><month>2</month><volume>190</volume><issue>(2)</issue><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">10657008</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmunzer</surname><given-names>BJ</given-names></name><name><surname>Scheiman</surname><given-names>JM</given-names></name><name><surname>Lehman</surname><given-names>GA</given-names></name><name><surname>Chak</surname><given-names>A</given-names></name><name><surname>Mosler</surname><given-names>P</given-names></name><name><surname>Higgins</surname><given-names>PD</given-names></name><etal/></person-group><article-title>U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.</article-title><source>N Engl J Med.</source><year>2012</year><month>4</month><volume>366</volume><issue>15</issue><fpage>1414</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">22494121</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>A</given-names></name><name><surname>Bechtold</surname><given-names>ML</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>Szary</surname><given-names>NM</given-names></name><name><surname>Puli</surname><given-names>SR</given-names></name><name><surname>Othman</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review.</article-title><source>Gastrointest Endosc.</source><year>2011</year><month>2</month><volume>73</volume><issue>(2)</issue><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">21295641</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazaki</surname><given-names>T</given-names></name><name><surname>Mado</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Shiono</surname><given-names>M</given-names></name></person-group><article-title>Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis.</article-title><source>J Gastroenterol.</source><year>2014</year><month>2</month><volume>49</volume><issue>(2)</issue><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">23612857</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>ML</given-names></name><name><surname>Overby</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>D</given-names></name></person-group><article-title>Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success.</article-title><source>Gastrointest Endosc.</source><year>2004</year><month>1</month><volume>59</volume><issue>(1)</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">14722540</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumonceau</surname><given-names>JM</given-names></name><name><surname>Rigaux</surname><given-names>J</given-names></name><name><surname>Kahaleh</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>CM</given-names></name><name><surname>Vandermeeren</surname><given-names>A</given-names></name><name><surname>Deviere</surname><given-names>J</given-names></name></person-group><article-title>Prophylaxis of post-ERCP pancreatitis: a practice survey.</article-title><source>Gastrointest Endosc.</source><year>2010</year><volume>71</volume><fpage>934</fpage><lpage>939</lpage><comment>939.e1&#x02013;2</comment><pub-id pub-id-type="pmid">20226455</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmunzer</surname><given-names>BJ</given-names></name><name><surname>Higgins</surname><given-names>PD</given-names></name><name><surname>Saini</surname><given-names>SD</given-names></name><name><surname>Scheiman</surname><given-names>JM</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Chak</surname><given-names>A</given-names></name><etal/></person-group><article-title>United States Cooperative for Outcomes Research in Endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data.</article-title><source>Am J Gastroenterol.</source><year>2013</year><month>3</month><volume>108</volume><issue>3</issue><fpage>410</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">23295278</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akshintala</surname><given-names>VS</given-names></name><name><surname>Hutfless</surname><given-names>SM</given-names></name><name><surname>Colantuoni</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>KJ</given-names></name><name><surname>Khashab</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis.</article-title><source>Aliment Pharmacol Ther.</source><year>2013</year><month>12</month><volume>38</volume><issue>(11&#x02013;12)</issue><fpage>1325</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">24138390</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>LH</given-names></name><name><surname>Qian</surname><given-names>JB</given-names></name><name><surname>Gu</surname><given-names>LG</given-names></name><name><surname>Qiu</surname><given-names>JW</given-names></name><name><surname>Ge</surname><given-names>ZM</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla.</article-title><source>J Gastroenterol Hepatol.</source><year>2011</year><month>7</month><volume>26</volume><issue>(7)</issue><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">21392105</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Flowchart of patients through the clinical protocol. PEP, post-endoscopic retrograde cholangiopancreatography pancreatitis.</p></caption><graphic xlink:href="crg-0012-0125-g01"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of patients undergoing ERCP</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Epinephrine <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Indomethacin <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Combination <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">33 (33.7)</td><td align="left" rowspan="1" colspan="1">41 (41.8)</td><td align="left" rowspan="1" colspan="1">24 (24.5)</td><td align="left" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">33 (35.1)</td><td align="left" rowspan="1" colspan="1">27 (28.7)</td><td align="left" rowspan="1" colspan="1">34 (36.2)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean age, years</td><td align="left" rowspan="1" colspan="1">59.59&#x000b1;15.680</td><td align="left" rowspan="1" colspan="1">58.06&#x000b1;17.125</td><td align="left" rowspan="1" colspan="1">59.62&#x000b1;15.369</td><td align="left" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" rowspan="1" colspan="1">PD dilation</td><td align="left" rowspan="1" colspan="1">1 (12.5)</td><td align="left" rowspan="1" colspan="1">4 (50.7)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">0.404</td></tr><tr><td align="left" rowspan="1" colspan="1">CBD stone</td><td align="left" rowspan="1" colspan="1">28 (34.1)</td><td align="left" rowspan="1" colspan="1">30 (36.6)</td><td align="left" rowspan="1" colspan="1">24 (29.3)</td><td align="left" rowspan="1" colspan="1">0.970</td></tr><tr><td align="left" rowspan="1" colspan="1">PD injection</td><td align="left" rowspan="1" colspan="1">2 (33.3)</td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (16.7)</td><td align="left" rowspan="1" colspan="1">0.687</td></tr><tr><td align="left" rowspan="1" colspan="1">PD cannulation</td><td align="left" rowspan="1" colspan="1">6 (50.0)</td><td align="left" rowspan="1" colspan="1">2 (16.7)</td><td align="left" rowspan="1" colspan="1">4 (33.3)</td><td align="left" rowspan="1" colspan="1">0.329</td></tr><tr><td align="left" rowspan="1" colspan="1">CBD dilation</td><td align="left" rowspan="1" colspan="1">48 (37.5)</td><td align="left" rowspan="1" colspan="1">45 (35.2)</td><td align="left" rowspan="1" colspan="1">35 (27.3)</td><td align="left" rowspan="1" colspan="1">0.343</td></tr><tr><td align="left" rowspan="1" colspan="1">Balloon dilation of sphincter of Oddi</td><td align="left" rowspan="1" colspan="1">16 (42.1)</td><td align="left" rowspan="1" colspan="1">12 (31.6)</td><td align="left" rowspan="1" colspan="1">10 (26.3)</td><td align="left" rowspan="1" colspan="1">0.533</td></tr><tr><td align="left" rowspan="1" colspan="1">Biliary stricture</td><td align="left" rowspan="1" colspan="1">13 (40.6)</td><td align="left" rowspan="1" colspan="1">10 (31.2)</td><td align="left" rowspan="1" colspan="1">9 (28.1)</td><td align="left" rowspan="1" colspan="1">0.712</td></tr><tr><td align="left" rowspan="1" colspan="1">Biliary duct tumor</td><td align="left" rowspan="1" colspan="1">3 (18.8)</td><td align="left" rowspan="1" colspan="1">7 (43.8)</td><td align="left" rowspan="1" colspan="1">6 (37.5)</td><td align="left" rowspan="1" colspan="1">0.389</td></tr><tr><td align="left" rowspan="1" colspan="1">Suspected SOD</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">2 (25.0)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td><td align="left" rowspan="1" colspan="1">0.808</td></tr><tr><td align="left" rowspan="1" colspan="1">Difficult cannulation</td><td align="left" rowspan="1" colspan="1">14 (25.0)</td><td align="left" rowspan="1" colspan="1">19 (33.9)</td><td align="left" rowspan="1" colspan="1">23 (41.1)</td><td align="left" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" rowspan="1" colspan="1">Sphincterotomy</td><td align="left" rowspan="1" colspan="1">51 (33.1)</td><td align="left" rowspan="1" colspan="1">53 (34.4)</td><td align="left" rowspan="1" colspan="1">50 (32.5)</td><td align="left" rowspan="1" colspan="1">0.421</td></tr><tr><td align="left" rowspan="1" colspan="1">Needle knife precut</td><td align="left" rowspan="1" colspan="1">7 (30.4)</td><td align="left" rowspan="1" colspan="1">7 (30.4)</td><td align="left" rowspan="1" colspan="1">9 (39.1)</td><td align="left" rowspan="1" colspan="1">0.610</td></tr><tr><td align="left" rowspan="1" colspan="1">Peri-ampullary diverticulum</td><td align="left" rowspan="1" colspan="1">17 (34.7)</td><td align="left" rowspan="1" colspan="1">16 (32.7)</td><td align="left" rowspan="1" colspan="1">16 (32.7)</td><td align="left" rowspan="1" colspan="1">0.872</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholecystectomy</td><td align="left" rowspan="1" colspan="1">13 (34.2)</td><td align="left" rowspan="1" colspan="1">13 (34.2)</td><td align="left" rowspan="1" colspan="1">12 (31.6)</td><td align="left" rowspan="1" colspan="1">0.976</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-amylase level, IU/L</td><td align="left" rowspan="1" colspan="1">88.4 (40.25)</td><td align="left" rowspan="1" colspan="1">98 (43.2)</td><td align="left" rowspan="1" colspan="1">96 (45.62)</td><td align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-lipase level, IU/L</td><td align="left" rowspan="1" colspan="1">101 (51.40)</td><td align="left" rowspan="1" colspan="1">92.5 (46.9)</td><td align="left" rowspan="1" colspan="1">90.1 (41.85)</td><td align="left" rowspan="1" colspan="1">0.605</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-amylase level (4 h), IU/L</td><td align="left" rowspan="1" colspan="1">264.5 (255.1)</td><td align="left" rowspan="1" colspan="1">286.3 (274.5)</td><td align="left" rowspan="1" colspan="1">269.1 (257.6)</td><td align="left" rowspan="1" colspan="1">0.460</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-amylase level (24 h), IU/L</td><td align="left" rowspan="1" colspan="1">642.1 (1,115)</td><td align="left" rowspan="1" colspan="1">676 (1,163.3)</td><td align="left" rowspan="1" colspan="1">615.4 (1,064.2)</td><td align="left" rowspan="1" colspan="1">0.542</td></tr></tbody></table><table-wrap-foot><fn><p>ERCP, endoscopic retrograde cholangiopancreatography; PD, pancreatic duct; CBD, common bile duct; SOD, sphincter of Oddi dysfunction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Outcomes of patients after endoscopic retrograde cholangiopancreatography</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Epinephrine <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Indomethacin <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Combination <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Pancreatitis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mild</td><td align="left" rowspan="1" colspan="1">1 (20)</td><td align="left" rowspan="1" colspan="1">4 (80)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (100)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (100)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate analysis of risk factors for post-ERCP pancreatitis in patients with and without pancreatitis</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Non-pancreatitis group, <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Pancreatitis group, <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Total (n = 704) <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PD dilation</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" rowspan="1" colspan="1">Suspected SOD</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholecystectomy</td><td align="left" rowspan="1" colspan="1">37 (97.4)</td><td align="left" rowspan="1" colspan="1">1 (2.6)</td><td align="left" rowspan="1" colspan="1">38 (100)</td><td align="left" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" rowspan="1" colspan="1">CBD stone</td><td align="left" rowspan="1" colspan="1">80 (97.6)</td><td align="left" rowspan="1" colspan="1">2 (2.4)</td><td align="left" rowspan="1" colspan="1">82 (100)</td><td align="left" rowspan="1" colspan="1">0.355</td></tr><tr><td align="left" rowspan="1" colspan="1">Difficult cannulation</td><td align="left" rowspan="1" colspan="1">130 (95.6)</td><td align="left" rowspan="1" colspan="1">6 (4.4)</td><td align="left" rowspan="1" colspan="1">136 (100)</td><td align="left" rowspan="1" colspan="1">0.343</td></tr><tr><td align="left" rowspan="1" colspan="1">Sphincterotomy</td><td align="left" rowspan="1" colspan="1">150 (97.4)</td><td align="left" rowspan="1" colspan="1">4 (2.6)</td><td align="left" rowspan="1" colspan="1">154 (100)</td><td align="left" rowspan="1" colspan="1">0.134</td></tr><tr><td align="left" rowspan="1" colspan="1">Needle knife precut</td><td align="left" rowspan="1" colspan="1">23 (100)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">23 (100)</td><td align="left" rowspan="1" colspan="1">0.403</td></tr><tr><td align="left" rowspan="1" colspan="1">PD cannulation</td><td align="left" rowspan="1" colspan="1">11 (91.7)</td><td align="left" rowspan="1" colspan="1">1 (8.3)</td><td align="left" rowspan="1" colspan="1">12 (100)</td><td align="left" rowspan="1" colspan="1">0.368</td></tr><tr><td align="left" rowspan="1" colspan="1">PD injection</td><td align="left" rowspan="1" colspan="1">6 (100)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">6 (100)</td><td align="left" rowspan="1" colspan="1">0.798</td></tr><tr><td align="left" rowspan="1" colspan="1">Balloon dilation of sphincter of Oddi</td><td align="left" rowspan="1" colspan="1">36 (94.7)</td><td align="left" rowspan="1" colspan="1">2 (5.3)</td><td align="left" rowspan="1" colspan="1">38 (100)</td><td align="left" rowspan="1" colspan="1">0.419</td></tr><tr><td align="left" rowspan="1" colspan="1">CBD dialation</td><td align="left" rowspan="1" colspan="1">123 (95.4)</td><td align="left" rowspan="1" colspan="1">5 (4.6)</td><td align="left" rowspan="1" colspan="1">128 (100)</td><td align="left" rowspan="1" colspan="1">0.571</td></tr><tr><td align="left" rowspan="1" colspan="1">Biliary stricture</td><td align="left" rowspan="1" colspan="1">30 (93.8)</td><td align="left" rowspan="1" colspan="1">2 (6.2)</td><td align="left" rowspan="1" colspan="1">32 (100)</td><td align="left" rowspan="1" colspan="1">0.330</td></tr><tr><td align="left" rowspan="1" colspan="1">Biliary duct tumor</td><td align="left" rowspan="1" colspan="1">15 (93.8)</td><td align="left" rowspan="1" colspan="1">1 (6.2)</td><td align="left" rowspan="1" colspan="1">14 (100)</td><td align="left" rowspan="1" colspan="1">0.462</td></tr><tr><td align="left" rowspan="1" colspan="1">Peri-ampullary diverticulum</td><td align="left" rowspan="1" colspan="1">47 (95.9)</td><td align="left" rowspan="1" colspan="1">2 (4.1)</td><td align="left" rowspan="1" colspan="1">49 (100)</td><td align="left" rowspan="1" colspan="1">0.571</td></tr><tr><td align="left" colspan="5" rowspan="1">Medication</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Epinephrine</td><td align="left" rowspan="1" colspan="1">66 (100)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">66 (100)</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indomethacin</td><td align="left" rowspan="1" colspan="1">62 (91.2)</td><td align="left" rowspan="1" colspan="1">6 (8.8)</td><td align="left" rowspan="1" colspan="1">68 (100)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Combination</td><td align="left" rowspan="1" colspan="1">57 (98.3)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">58 (100)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>ERCP, endoscopic retrograde cholangiopancreatography; PD, pancreatic duct; CBD, common bile duct; SOD, sphincter of Oddi dysfunction.</p></fn></table-wrap-foot></table-wrap></floats-group></article>